topotecan,ifosfamide
gsk
['sarcoma', 'reecur']
#asco2022 #mlmasco - 94% probability of ifosfamide being slightly superior to topotecan/cyclofosfamide in relapsed/primary refractory ewing sarcomas in the reecur. a practical basket trial design. very hard to interpret. little appl. to age &gt;14. confused, but on a level 
"What we cannot speak about we must pass over in silence" (L. Wittgenstein)